Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Q2 2026 Earnings Presentation
6 slides from Definium Therapeutics's earnings presentation, Aug 6, 2026
Slide 1: Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 6, 2026 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy Topline results from Phase 3 GAD st
Slide 2: Announced positive topline results from Phase 3 Emerge study
Announced positive topline results from Phase 3 Emerge study (MDD) with 149 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo. Key findings included: Met the primary endpoint and all key secondary efficacy endpoints with a high degree of statistical significance. Demonstrated a stat
Slide 3: Second Quarter 2026 Financial Results
million in legal and patent expenses, and an increase of $0.7 million in other miscellaneous administrative expenses. Net loss. Net loss for the three months ended June 30, 2026 was significantly impacted by an $86.2 million non-cash increase in the fair value of warrant liabilities associated with
Slide 4: Forward-Looking Statements
identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not li
Slide 5: Consolidated Balance Sheets
Definium Therapeutics, Inc. Consolidated Balance Sheets June 30, 2026 December 31, (in thousands, except share amounts) (unaudited) 2025 Assets Current assets: Cash and cash equivalents $ 655,267 $ 257,837 Short-term investments 428,612 153,756 Prepaid and other current assets 8,222 7,727 Total curr
Slide 6: Consolidated Statements of Operations and Comprehensive Loss
Definium Therapeutics, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2026 2025 2026 2025 Operating expenses: Research and development $ 48,665 $ 29,809 $ 90,149 $
Definium Therapeutics — Q2 2026 Earnings Presentation on 6ix